Physician profile
Zsofia Intody
NPI 1023344793
$620.76
in general payments reported to CMS, 2019-2025
13 companies · $94.75 in 2025
The $94.75 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $75.13 · 2021: $27.90 · 2022: $90.97 · 2023: $92.33 · 2024: $88.10 · 2025: $94.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $189.09 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $130.34 | 2019-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $49.98 | 2019-2022 | |
| Tris Pharma INC | $46.17 | 2019 | |
| Ucb, INC. | $41.66 | 2024 | Nayzilam |
| Cipher Pharmaceuticals US LLC | $39.06 | 2025 | Natroba, Spinosad |
| Ars Pharmaceuticals Operations, INC. | $25.38 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $24.25 | 2022 | |
| Alk-Abello, INC | $18.69 | 2023 | Odactra, Grastek |
| Kowa Pharmaceuticals America, INC. | $15.68 | 2024 | Zoryve |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 | |
| Genentech USA, INC. | $13.66 | 2020 | |
| Shire North American Group INC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zsofia Intody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.